Image‑Guided Brachytherapy for Cervical Cancer – Evidence‑Based Guidelines

1. Fundamental Role of Brachytherapy

• The American Brachytherapy Society (ABS) states that brachytherapy is an essential, non‑negotiable component of definitive treatment for all patients with intact cervical cancer who are not surgical candidates, and it cannot be substituted by conformal external‑beam techniques such as IMRT or SBRT for central disease. 1, 2

2. Applicator Selection and Technique

• Intracavitary applicators (intra‑uterine tandem with vaginal colpostats—ovoids, ring, or cylinder) are the standard technique and should be chosen according to patient anatomy and tumor extent. 1
• Interstitial brachytherapy is reserved for rare situations where tumor geometry precludes an intracavitary approach and must be performed only by clinicians and institutions with proven expertise. 1
• Brachytherapy should be initiated during the latter portion of external‑beam radiotherapy (EBRT) after sufficient primary‑tumor regression allows satisfactory applicator geometry. 1

3. Dose Prescription and Planning

• The combined dose from EBRT + brachytherapy to point A must be ≥ 80 Gy (LDR‑equivalent) for small tumors and ≥ 85 Gy for larger tumors. 1, 3
• The traditional point A dosing system remains the standard reference because of extensive experience and proven tumor‑control outcomes. 1
• When using 3‑D image‑guided brachytherapy, the conventional point A prescription must be retained to avoid tumor under‑dosage. 1
• Doses are routinely calculated at standardized point A, point B, and at bladder and rectal reference points. 1
• For high‑dose‑rate (HDR) brachytherapy, the linear‑quadratic model is used to convert nominal HDR doses to biologically equivalent low‑dose‑rate (LDR) doses. 1
• A common HDR regimen consists of five insertions with tandem + colpostats, each delivering 6 Gy to point A (total 30 Gy in 5 fractions), which is biologically equivalent to 40 Gy LDR. 1

4. Integration with External Beam Radiotherapy (EBRT)

• An initial EBRT dose of 40–45 Gy to the whole pelvis is required to achieve tumor shrinkage before optimal intracavitary placement. 3
• CT‑based treatment planning with conformal blocking and rigorous dosimetric verification is the standard of care for the EBRT component. 3

5. Special Clinical Scenarios

• In post‑hysterectomy patients—especially those with positive vaginal mucosal margins—vaginal‑cylinder brachytherapy should be employed as a boost to EBRT. 1, 3

6. Toxicity Reporting (RetroEMBRACE Cohort)

• Grade 3–5 vaginal morbidity at 5 years was observed in 5 % of patients receiving image‑guided brachytherapy. 1

7. Quality Assurance and Technical Requirements

• The ABS emphasizes meticulous attention to reproducibility, including precise target and normal‑tissue definitions, management of patient and organ motion, soft‑tissue deformation, and comprehensive dosimetric and physics quality‑assurance procedures for IMRT and related highly conformal technologies. 1, 2

All statements are derived from cited evidence and reflect the current consensus of the American Brachytherapy Society and related guideline bodies.

Brachytherapy for Cervical Cancer

Patient Selection and Timing

• The National Comprehensive Cancer Network recommends brachytherapy as a critical component of definitive therapy for all patients with intact cervical cancer who are not surgical candidates 4, 5, 6, 7
• Brachytherapy should be initiated toward the latter part of external beam radiotherapy treatment, after sufficient primary tumor regression has occurred to permit satisfactory applicator geometry 4, 5
• For highly selected very early disease (stage IA2), brachytherapy alone without external beam radiation may be an option 4, 5

Pre-Procedure Planning

• MRI remains the gold standard for soft tissue assessment, with 86% agreement with surgical pathology for tumor size and 71-88% sensitivity for invasion extent 8
• CT-based treatment planning with conformal blocking and dosimetry is considered standard care for external beam component 6, 7, 9
• Initial EBRT of 40-45 Gy to the whole pelvis is necessary to obtain tumor shrinkage before optimal intracavitary placements 6, 7, 9

Applicator Selection and Placement

• The National Comprehensive Cancer Network recommends using an intrauterine tandem combined with vaginal colpostats (ovoids, ring, or cylinder) based on patient and tumor anatomy 4, 5
• Interstitial brachytherapy should only be used in rare cases when tumor geometry renders intracavitary brachytherapy infeasible, and only by individuals and institutions with appropriate experience and expertise 4, 5

Dosing Parameters

• The total doses from brachytherapy and external beam radiation to point A must reach at least 80 Gy for small tumors and ≥85 Gy for larger tumors 6, 7, 9, 8
• The point A dosing system remains the standard based on extensive experience and tumor control results 4, 5
• When implementing 3D image-guided approaches, traditional point A dosing must not be abandoned to avoid underdosing tumors 5, 8

Treatment Delivery Sequence

• The entire radiation course (including both external beam and brachytherapy components) should be completed within 8 weeks 6, 7, 9
• Extending treatment beyond 6-8 weeks results in approximately 0.5-1% decrease in pelvic control and cause-specific survival for each extra day 6, 7, 9
• Concurrent cisplatin-based chemotherapy should be administered during external beam radiotherapy for most patients with cervical cancer 4, 5

Image-Guided Brachytherapy Considerations

• Current 3D image-guided techniques optimize implant dose coverage of tumor while potentially reducing dose to adjacent bladder, rectum, and bowel structures 4, 5
• Highly conformal external beam therapies should not be used as routine alternatives to brachytherapy for treatment of central disease in patients with an intact cervix 5

Dosimetry Standards

• Dosimetry should be used according to International Commission of Radiation Units recommendations 10
• Doses should be calculated at standardized point A, point B, and bladder and rectal points 4, 5
• For limited-stage disease, the combination of external radiotherapy/brachytherapy must deliver a total dose of 60 Gy to the central pelvis and 45-50 Gy to the lateral pelvic area 10